Literature DB >> 7920309

Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versus-host disease.

M Imamura1, S Hashino, H Kobayashi, S Kubayashi, S Hirano, T Minagawa, J Tanaka, Y Fujii, M Kobayashi, M Kasai.   

Abstract

In patients with acute graft-versus-host disease (GVHD), IL-6 gradually increased > 14 days before clinical onset of acute GVHD and decreased when acute GVHD disappeared. Interferon-gamma (IFN gamma) levels increased < 14 days before clinical acute GVHD and decreased at the disappearance of acute GVHD. Tumor necrosis factor-alpha (TNF alpha) levels increased almost simultaneously with the onset of acute GVHD and also decreased when it disappeared. However, these results do not necessarily mean that the increased levels of IL-6, IFN gamma and TNF alpha induced acute GVHD; they merely show that acute GVHD is observed more frequently in patients with increased IL-6, IFN gamma and TNF alpha levels than in those with normal levels. Although increased IL-6 levels were also observed in patients without acute GVHD, concomitant increase of IFN gamma and TNF alpha was not detected in such cases, showing that IL-6 can be increased by even graft-versus-host reaction (GVHR) which may not develop into clinical acute GVHD. Taken together, acute GVHD appeared to be induced by synergistic interaction of IL-6, IFN gamma and TNF alpha, consistent with a cytokine cascade. A similar interaction of IL-6 and TNF alpha was also observed in chronic GVHD. Although IFN gamma levels were slightly increased in chronic GVHD and sometimes aggravated the disease status, IL-6 and TNF alpha appeared to be more closely involved in the induction of chronic GVHD. In autologous BMT, increased cytokine levels were not observed unless IL-2 was administered.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7920309

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  38 in total

1.  Regulation of acute graft-versus-host disease by microRNA-155.

Authors:  Parvathi Ranganathan; Catherine E A Heaphy; Stefan Costinean; Nicole Stauffer; Caroline Na; Mehdi Hamadani; Ramasamy Santhanam; Charlene Mao; Patricia A Taylor; Sukhinder Sandhu; Gang He; Arwa Shana'ah; Gerard J Nuovo; Alessandro Lagana; Luciano Cascione; Susanna Obad; Oliver Broom; Sakari Kauppinen; John C Byrd; Michael Caligiuri; Danilo Perrotti; Gregg A Hadley; Guido Marcucci; Steven M Devine; Bruce R Blazar; Carlo M Croce; Ramiro Garzon
Journal:  Blood       Date:  2012-03-09       Impact factor: 22.113

2.  Attenuation of acute graft-versus-host disease in the absence of the transcription factor RORγt.

Authors:  LeShara M Fulton; Michael J Carlson; James M Coghill; Laura E Ott; Michelle L West; Angela Panoskaltsis-Mortari; Dan R Littman; Bruce R Blazar; Jonathan S Serody
Journal:  J Immunol       Date:  2012-07-09       Impact factor: 5.422

Review 3.  Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease.

Authors:  Tomomi Toubai; John Magenau
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

4.  Cotransplantation of marrow stromal cells may prevent lethal graft-versus-host disease in major histocompatibility complex mismatched murine hematopoietic stem cell transplantation.

Authors:  Nak Gyun Chung; Dae Chul Jeong; Soo Jeong Park; Byung Ock Choi; Bin Cho; Hack Ki Kim; Chung Sik Chun; Jong Ho Won; Chi Wha Han
Journal:  Int J Hematol       Date:  2004-11       Impact factor: 2.490

Review 5.  Genomic and proteomic analysis of allogeneic hematopoietic cell transplant outcome. Seeking greater understanding the pathogenesis of GVHD and mortality.

Authors:  John A Hansen
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

6.  Tocilizumab for the treatment of steroid refractory graft-versus-host disease.

Authors:  William R Drobyski; Marcelo Pasquini; Kathy Kovatovic; Jeanne Palmer; J Douglas Rizzo; Ayman Saad; Wael Saber; Parameswaran Hari
Journal:  Biol Blood Marrow Transplant       Date:  2011-07-13       Impact factor: 5.742

Review 7.  Plasma biomarkers in graft-versus-host disease: a new era?

Authors:  Sophie Paczesny; John E Levine; Thomas M Braun; James L M Ferrara
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

8.  Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease.

Authors:  Xiao Chen; Rupali Das; Richard Komorowski; Amy Beres; Martin J Hessner; Masahiko Mihara; William R Drobyski
Journal:  Blood       Date:  2009-06-02       Impact factor: 22.113

9.  Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group.

Authors:  Hisaki Fujii; Geoff Cuvelier; Kevin She; Soudabeh Aslanian; Hiromi Shimizu; Amina Kariminia; Mark Krailo; Zhengjia Chen; Rob McMaster; Axel Bergman; Frederick Goldman; Stephen A Grupp; Donna A Wall; Andrew L Gilman; Kirk R Schultz
Journal:  Blood       Date:  2007-10-09       Impact factor: 22.113

Review 10.  Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation.

Authors:  Masahiro Imamura; Junji Tanaka
Journal:  Korean J Intern Med       Date:  2009-11-27       Impact factor: 3.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.